|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nemeth JA, Yousif R, Herzog M, Che M,
Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher
ML: Matrix metalloproteinase activity, bone matrix turnover, and
tumor cell proliferation in prostate cancer bone metastasis. J Natl
Cancer Inst. 94:17–25. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lokeshwar BL: MMP inhibition in prostate
cancer. Ann NY Acad Sci. 878:271–289. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song H, Li Y, Lee J, Schwartz AL and Bu G:
Low-density lipoprotein receptor-related protein 1 promotes cancer
cell migration and invasion by inducing the expression of matrix
metalloproteinases 2 and 9. Cancer Res. 69:879–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Srivastava P, Lone TA, Kapoor R and Mittal
RD: Association of promoter polymorphisms in MMP2 and TIMP2 with
prostate cancer susceptibility in North India. Arch Med Res.
43:117–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
dos Reis ST, Villanova FE, Andrade PM,
Pontes J Jr, de Sousa-Canavez JM, Sañudo A, Antunes AA, Dall'oglio
MF, Srougi M and Leite Moreira KR: Matrix metalloproteinase-2
polymorphism is associated with prognosis in prostate cancer. Urol
Oncol. 28:624–627. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trudel D, Fradet Y, Meyer F, Harel F and
Têtu B: Membrane-type-1 matrix metalloproteinase, matrix
metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in
prostate cancerIdentification of patients with poor prognosis by
immunohistochemistry. Hum Pathol. 39:731–739. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong WD, Han ZD, He HC, Bi XC, Dai QS,
Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, et al: CD147, MMP-1, MMP-2
and MMP-9 protein expression as significant prognostic factors in
human prostate cancer. Oncology. 75:230–236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peters JL, Sutton AJ, Jones DR, Abrams KR
and Rushton L: Comparison of two methods to detect publication bias
in meta-analysis. JAMA. 295:676–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia ZY, Ma M and Yu NN: Expression and
significance of COX-2 and MMP-2 in prostate cancer. Shandong Med J.
50:52–53. 2010.
|
|
12
|
Ma Z: Expression of CD147 and MMP-2 in
prostate cancer tissues and the correlation study of it. Tianjin.
9–12. 2014.(In Chinese).
|
|
13
|
Li DD: The expression and significance of
MMP-2 and TIMP-2 in benign and malignant prostatic lesions.
Tianjin. 9–11. 2013.(In Chinese).
|
|
14
|
Escaff S, Fernández JM, González LO,
Suárez A, González-Reyes S, González JM and Vizoso FJ: Comparative
study of stromal metalloproteases expression in patients with
benign hyperplasia and prostate cancer. J Cancer Res Clin Oncol.
137:551–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang XY, Hong BF, Chen GF, Lu YL and
Zhong M: Significance of MMP2 and MMP9 expression in prostate
cancer. Zhonghua Nan Ke Xue. 11359–361. (364)2005.(In Chinese).
PubMed/NCBI
|
|
16
|
Wu YD, Liu BQ, Zhang XP, et al: Detection
osteopontin and matrix metalloproteinase-2 in prostate cancer.
Zhengzhou Da Xue Xue Bao Yi Xue Ban. 40:654–656. 2005.(In
Chinese).
|
|
17
|
Wu J and Zhang C: Expression of VEGF MMP-2
and MVD in prostatic cancer and its relation to clinic pathology.
Mod Med Health. 25:3203–3204. 2009.
|
|
18
|
Center MM, Jemal A, Lortet-Tieulent J,
Ward E, Ferlay J, Brawley O and Bray F: International variation in
prostate cancer incidence and mortality rates. Eur Urol.
61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Ji GY, Li XM, et al: The
influence of mass screening for prostate cancer on the diagnostic
status of the clinical prostate cancer. Chin J Urol. 25:103–105.
2004.
|
|
20
|
Amălinei C, Căruntu ID, Giuşcă SE and
Bălan RA: Matrix metalloproteinases involvement in pathologic
conditions. Rom J Morphol Embryol. 51:215–228. 2010.PubMed/NCBI
|
|
21
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases:
Structure function, and biochemistry. Circ Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI
|
|
25
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gohji K, Fujimoto N, Hara I, Fujii A,
Gotoh A, Okada H, Arakawa S, Kitazawa S, Miyake H, Kamidono S, et
al: Serum matrix metalloproteinase-2 and its density in men with
prostate cancer as a new predictor of disease extension. Int J
Cancer. 79:96–101. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Shi J, Feng J, Klocker H, Lee C
and Zhang J: Type IV collagenase (matrix metalloproteinase-2 and
−9) in prostate cancer. Prostate Cancer Prostatic Dis. 7:327–332.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lovaas JD, Zhu L, Chiao CY, Byles V,
Faller DV and Dai Y: SIRT1 enhances matrix metalloproteinase-2
expression and tumor cell invasion in prostate cancer cells.
Prostate. 73:522–530. 2013. View Article : Google Scholar : PubMed/NCBI
|
